Rigel Pharmaceuticals (RIGL) Research & Development (2010 - 2026)

Rigel Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• On a quarterly basis, Research & Development rose 38.41% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $36.5 million, a 41.66% increase from a year earlier, with the FY2025 full-year figure at $33.3 million, up 42.41% from the prior year.
• Research & Development climbed to $11.7 million in Q1 2026 per RIGL's latest filing, from $10.7 million in the prior quarter.
• Across five years, Research & Development topped out at $15.5 million in Q1 2022 and bottomed at $2.5 million in Q4 2022.
• The 5-year median for Research & Development is $6.8 million (2025), against an average of $8.3 million.
• Across the five-year window, Research & Development slumped 81.21% in 2022 and surged 89.72% in 2025, its largest moves.
• Year by year, Research & Development stood at $2.5 million in 2022, then grew by 27.44% to $3.2 million in 2023, then jumped by 76.77% to $5.6 million in 2024, then jumped by 89.72% to $10.7 million in 2025, then advanced by 9.27% to $11.7 million in 2026.
• Per Business Quant, the three latest RIGL Research & Development figures stand at $11.7 million (Q1 2026), $10.7 million (Q4 2025), and $7.4 million (Q3 2025).